Advanced Drug Delivery Reviews

Editorial Board
pp. ii-ii(1)

Peptide and protein pegylation II - clinical evaluation
pp. 1259-1260(2)

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
pp. 1261-1277(17)
Authors: Caliceti P.; Veronese F.M.

PEGylation of growth hormone-releasing hormone (GRF) analogues
pp. 1279-1291(13)
Authors: Esposito P.; Barbero L.; Caccia P.; Caliceti P.; D'Antonio M.; Piquet G.; Veronese F.M.

Pegaspargase: a review of clinical studies
pp. 1293-1302(10)
Author: Graham M.L.

Pegvisomant in the treatment of acromegaly
pp. 1303-1314(12)
Authors: Parkinson C.; Scarlett J.A.; Trainer P.J.

Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases
pp. 1315-1336(22)
Authors: Edwards C.K.; Martin S.W.; Seely J.; Kinstler O.; Buckel S.; Bendele A.M.; Ellen Cosenza M.; Feige U.; Kohno T.

Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction
pp. 1337-1345(9)
Authors: Moreadith R.W.; Collen D.